HIV and Cardiovascular Disease: A Tale of Two Epidemics

Presenters

Marshall J. Glesby, MD, PhD
Weill Cornell Medicine

Start

September 25, 2018 - 10:00 AM

End

September 25, 2018 - 11:15 AM

Add to iCal Calendar

Overview

Assessment of Needs

The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians.

This webinar will summarize the epidemiology and pathogenesis of cardiovascular disease in people living with HIV, with a focus on coronary heart disease. It will also address the evaluation and management of cardiovascular risk factors in this population.

Learning Objectives

Upon completion of this webinar, learners will be able to:

  • Summarize the epidemiology of coronary heart disease in the HIV population
  • Describe the roles of HIV-related factors and antiretroviral therapy in the pathogenesis of coronary heart disease
  • Discuss the limitations of current approaches to estimating cardiovascular risk in people living with HIV

Registration

Who Should Attend

This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.

Registration closes on Monday, September 24, 2018, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration“at”iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”

Dr Glesby has received research support to Weill Cornell Medicine from Gilead Sciences for an investigator-initiated research study (Updated 09/18/18)

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

This program is approved for 1.25 hours of pharmacotherapy credit.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.25 hours (0.125 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-18-305-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS
Gilead Sciences, Inc
ViiV Healthcare

SILVER SUPPORTERS
Janssen Therapeutics
Merck

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.